Nasdaq Biotechnology Ishares ETF (IBB)
$102.35 0.00 (0.00%)
19:20 EDT IBB Stock Quote Delayed 15 Minutes
Previous Close $102.35
Market Cap 8.90B
PE Ratio -
Volume (Avg. Vol.)
Day's Range 102.35 - 102.35
52-Week Range 89.01 - 116.25
Dividend & Yield 0.31 (0.31%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
- From InvestorPlace
- From the Web
Bitcoin, Biotech, Micron and Starbucks were our top stock trades to watch. Here's how the charts are setting up going into Friday.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Memory stocks like Micron and semiconductor stocks like AMD were on the move in the Nasdaq today. Intel and Cisco weren't so lucky though.
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
Amid ongoing industry consolidation, attractive valuations and a strong broad market, catalysts are in place for more upside for biotech ETFs.
The charts for the IBB ETF in multiple time frames suggest the recent rally in biotech stocks is overdone for the time being.
This morning I am recommending a bearish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).
Biotech ETFs lagged in 2018, but that doesn't mean there aren't healthcare funds to consider for 2019.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
PFE is a proven survivor stock and it now sits on a potential long term technical breakout. Go long its potential with confidence.
Large-cap biotech stocks as a group rallied along with the broader stock market on Wednesday. While so doing, some big names like AMGN stock broke past key near-term technical resistance.
The biotech sector peaked in 2015. While it bounced back from lows, biotech ETFs give investors exposure to the sector as it recovers.
Both biotech stocks and big pharma stocks involve a different mindset. Treat biotech stocks like options and big pharma stocks like ETFs.
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!